Last reviewed · How we verify
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension
A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese hypertension patients
Details
| Lead sponsor | Lee's Pharmaceutical Limited |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 304 |
| Start date | 2015-09 |
| Completion | 2018-08 |
Conditions
- Hypertension
Interventions
- Azilsartan tablets
- Azilsartan placebo tablets
- Olmesartan medoxomil tablets
- olmesartan medoxomil placebo tablets
Primary outcomes
- Decrease of sitting diastolic blood pressure at week 16 — 16 weeks
Countries
China